Related Experiment Video
Updated: Dec 21, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Dantrolene reduces CaMKIIδC-mediated atrial arrhythmias
Steffen Pabel1, Julian Mustroph1, Thea Stehle1
1Department of Internal Medicine II, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
Insights
Dantrolene effectively reduces abnormal calcium leaks in atrial fibrillation (AF) by targeting CaMKII activity. This study shows dantrolene suppresses AF-inducing arrhythmias in mice, suggesting its potential as an antiarrhythmic drug.
Area of Science:
- Cardiovascular Research
- Molecular Cardiology
- Electrophysiology
Background:
- Atrial fibrillation (AF) involves increased sarcoplasmic reticulum (SR) Ca2+ leak, mediated by CaMKII, promoting arrhythmias.
- Dantrolene stabilizes the cardiac ryanodine receptor, a key component of SR Ca2+ release.
Purpose of the Study:
- To investigate the effects of dantrolene on CaMKII-mediated arrhythmogenesis in human and mouse atria.
- To assess dantrolene's potential as an antiarrhythmic therapy for AF.
Main Methods:
- Isolated human and mouse atrial cardiomyocytes (CMs) were studied.
- Techniques included confocal microscopy (Fluo-4) and patch-clamp.
- In vivo studies used catheter-based burst stimulations in mice overexpressing CaMKIIδC (TG) and wildtype (WT).
Main Results:
- Dantrolene significantly reduced Ca2+ spark frequency and SR Ca2+ leak in AF CMs and TG mice.
- Dantrolene diminished diastolic SR Ca2+ waves and afterdepolarizations in TG mice.
- In vivo, dantrolene strongly suppressed AF inducibility in TG mice.
Conclusions:
- Dantrolene effectively reduces CaMKII-mediated atrial arrhythmogenesis.
- Dantrolene shows promise as an antiarrhythmic drug for AF patients with elevated CaMKII activity.
Aims:
In atrial fibrillation (AF), an increased diastolic Ca2+ leak from the sarcoplasmic reticulum (SR) mediated by calcium/calmodulin-dependent-protein-kinaseIIδC (CaMKII) can serve as a substrate for arrhythmia induction and persistence. Dantrolene has been shown to stabilize the cardiac ryanodine-receptor. This study investigated the effects of dantrolene on arrhythmogenesis in human and mouse atria with enhanced CaMKII activity.
Methods And Results:
Human atrial cardiomyocytes (CMs) were isolated from patients with AF. To investigate CaMKII-mediated arrhythmogenesis, atrial CMs from mice overexpressing CaMKIIδC (TG) and the respective wildtype (WT) were studied using confocal microscopy (Fluo-4), patch-clamp technique, and in vivo atrial catheter-based burst stimulations. Dantrolene potently reduced Ca2+ spark frequency (CaSpF) and diastolic SR Ca2+ leak in AF CMs. Additional CaMKII inhibition did not further reduce CaSpF or leak compared to dantrolene alone. While the increased SR CaSpF and leak in TG mice were reduced by dantrolene, no effects could be detected in WT. Dantrolene also potently reduced the pathologically enhanced frequency of diastolic SR Ca2+ waves in TG without having effects in WT. As an increased diastolic SR Ca2+ release can induce a depolarizing transient inward current, we could demonstrate that the incidence of afterdepolarizations in TG, but not in WT, mice was significantly diminished in the presence of dantrolene. To translate these findings into an in vivo situation we could show that dantrolene strongly suppressed the inducibility of AF in vivo in TG mice.
Conclusion:
Dantrolene reduces CaMKII-mediated atrial arrhythmogenesis and may therefore constitute an interesting antiarrhythmic drug for treating patients with atrial arrhythmias driven by an enhanced CaMKII activity, such as AF.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inotropic Agents

